Common use of SUPPLEMENTAL INDENTURES 34 Clause in Contracts

SUPPLEMENTAL INDENTURES 34. Section 9.01 Supplemental Indentures Without the Consent of Securityholders 34 Section 9.02 Supplemental Indentures With Consent of Securityholders 35 Section 9.03 Effect of Supplemental Indentures 36 Section 9.04 Securities Affected by Supplemental Indentures 36 Section 9.05 Execution of Supplemental Indentures 36 ARTICLE 10 SUCCESSOR ENTITY 37 Section 10.01 Company May Consolidate, Etc. 37 Section 10.02 Successor Entity Substituted 37 ARTICLE 11 SATISFACTION AND DISCHARGE 38 Section 11.01 Satisfaction and Discharge of Indenture 38 Section 11.02 Discharge of Obligations 38 Section 11.03 Deposited Moneys to be Held in Trust 38 Section 11.04 Payment of Moneys Held by Paying Agents 39 Section 11.05 Repayment to Company 39 ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 39 Section 12.01 No Recourse 39 ARTICLE 13 MISCELLANEOUS PROVISIONS 40 Section 13.01 Effect on Successors and Assigns 40 Section 13.02 Actions by Successor 40 Section 13.03 Surrender of Company Powers 40 Section 13.04 Notices 40 Section 13.05 Governing Law; Jury Trial Waiver 40 Section 13.06 Treatment of Securities as Debt 40 Section 13.07 Certificates and Opinions as to Conditions Precedent 41 Section 13.08 Payments on Business Days 41 Section 13.09 Conflict with Trust Indenture Act 41 Section 13.10 Counterparts 41 Section 13.11 Separability 41 Section 13.12 Compliance Certificates 42 Section 13.13 Patriot Act 42 TABLE OF CONTENTS (CONTINUED) PAGE Section 13.14 Force Majeure 42 Section 13.12 Table of Contents; Headings 42

SUPPLEMENTAL INDENTURES 34. Section 9.01 Supplemental Indentures Without the Consent of Securityholders 34 Section 9.02 Supplemental Indentures With Consent of Securityholders 35 Section 9.03 Effect of Supplemental Indentures 36 35 Section 9.04 Securities Affected by Supplemental Indentures 36 35 Section 9.05 Execution of Supplemental Indentures 36 ARTICLE 10 SUCCESSOR ENTITY 37 36 Section 10.01 Company May Consolidate, Etc. 37 36 Section 10.02 Successor Entity Substituted 37 ARTICLE 11 SATISFACTION AND DISCHARGE 38 37 Section 11.01 Satisfaction and Discharge of Indenture 38 37 Section 11.02 Discharge of Obligations 38 Section 11.03 Deposited Moneys to be Held in Trust 38 Section 11.04 Payment of Moneys Held by Paying Agents 39 38 Section 11.05 Repayment to Company 39 38 ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 39 Section 12.01 No Recourse 39 ARTICLE 13 MISCELLANEOUS PROVISIONS 40 39 Section 13.01 Effect on Successors and Assigns 40 39 Section 13.02 Actions by Successor 40 39 Section 13.03 Surrender of Company Powers 40 39 Section 13.04 Notices 40 39 Section 13.05 Governing Law; Jury Trial Waiver 40 Section 13.06 Treatment of Securities as Debt 40 Section 13.07 Certificates and Opinions as to Conditions Precedent 41 40 Section 13.08 Payments on Business Days 41 40 Section 13.09 Conflict with Trust Indenture Act 41 Section 13.10 Counterparts 41 Section 13.11 Separability 41 Section 13.12 Compliance Certificates 42 41 Section 13.13 Patriot Act 42 TABLE OF CONTENTS (CONTINUED) PAGE 41 Section 13.14 Force Majeure 42 Section 13.12 Table of Contents; Headings 4242 INDENTURE, dated as of [●], 20 , among Aurinia Pharmaceuticals Inc., an Alberta corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):